Autoimmune diseases refer to a group of approximately 100 different diseases in which the body’s immune system, mistakenly attacks and destroys a patient’s own tissue (self). There is currently no cure for autoimmune diseases, and current treatments rely on general, non-specific suppression of immune system function, frequently resulting in unacceptable side effects including infection and cancer.

There is a large unmet need for improved treatments that can suppress immune activity (restore immune tolerance) to specific organs without causing generalized immune suppression.

Treg therapy has the potential to create organ-specific immune suppression, while avoiding the general immune suppression associated with current therapies. Unlike cell therapy ex vivo expansion of Treg cells, Parvus pMHC nanomedicines harness the patient’s own immune system to trigger in vivo expansion of antigen-specific Treg cells. These Treg cells traffic to inflamed tissues and suppress local pathogenic immune responses without impairing normal immune function and as such, hold great promise for patients suffering from autoimmune diseases and chronic inflammatory conditions.

Jord Cowan
Vice President of Operations
Louis Demers
Senior Vice President CMC
Sarah Grimberg
Senior Director Clinical Operations
Pere Santamaria, PhD, MD
Founder & Chief Scientific Officer, Board Member
Peter Strumph
Chief Executive Officer, Board Member
Joanne B.L. Tan, PhD
Senior Vice President Research and Development
Daniel C. Adelman, MD
Matthew J. Hogan, MBA
Charles Johnson, MB.ChB, FCP (SA)
Hugh Young Rienhoff, Jr. MD
Executive Chairman
Pere Santamaria, PhD, MD
Founder & Chief Scientific Officer, Board Member
Peter Strumph
Chief Executive Officer, Board Member
Louis
Ben
Vanessa
Lesiena
Leo
Joel
Chris L
Rolando
Wing
Jord
Peter
Janelle
Mia
Jonathan
Alex
Sarah
Joanne
Jessie
Maheeshi

If you are interested in discussing a collaboration or partnership opportunity, contact info@parvustx.com.